Cynapsus to Announce Top-Line Results from the CTH-105 Phase 2 Study on November 19, 2014
18 November 2014 - 10:40PM
Business Wire
- Press Release announcing results at
6:00 a.m. Eastern time
- Conference call to present results to
be held at 8:00 a.m. Eastern time
Cynapsus Therapeutics Inc. (TSX-V:CTH) (OTCQX:CYNAF), a
specialty pharmaceutical company focused on Parkinson’s disease,
announces the Company will report results from its CTH-105 Phase 2
clinical trial of APL-130277 for the treatment of OFF motor
symptoms of Parkinson’s disease on Wednesday, November 19, 2014 at
6:00 a.m. Eastern time. APL-130277 is the Company’s fast-acting,
sublingual, thin film strip formulation of apomorphine.
Cynapsus management will host a conference call with
accompanying slides on Wednesday, November 19, 2014 at 8:00 a.m.
Eastern time. Shareholders and other interested parties can
participate in the call by dialing 888-883-4599 (domestic) or
484-653-6821 (international) and referencing conference ID number
37666252. The call and slides will also be webcast live on the
Company's website at www.cynapsus.ca on the Calendar and Alerts
page under Investor Relations.
A replay of the conference call will be accessible beginning two
hours after its completion through November 26, 2014 by dialing
855-859-2056 (domestic) or 404-537-3406 (international) and
referencing conference ID number 37666252. The call and slides will
also be archived for 90 days on the Company's website at
www.cynapsus.ca on the Calendar and Alerts page under Investor
Relations.
About Cynapsus
Cynapsus is a specialty pharmaceutical company developing a
sublingual thin filmstrip for the acute rescue of OFF motor
symptoms of Parkinson’s disease. Cynapsus’ drug candidate,
APL-130277, is an easy-to-use, fast-acting formulation of
apomorphine, which is the only approved drug (in the United States,
Europe, Japan and other countries) to rescue patients from OFF
episodes. Cynapsus is focused on maximizing the value of APL-130277
by completing pivotal studies in advance of a 505(b)(2) New Drug
Application (NDA) expected to be submitted in 2016.
More than 1 million people in the U.S. and an estimated 4 to 6
million people globally suffer from Parkinson's disease.
Parkinson’s disease is a chronic and progressive neurodegenerative
disease that impacts motor activity, and its prevalence is
increasing with the aging of the population. OFF episodes are a
complication of Parkinson’s disease that leave patients rigid and
unable to move and communicate. An estimated one quarter to one
half of all people with Parkinson’s disease whose symptoms are
otherwise managed with ongoing drug therapy experience OFF episodes
at least once daily and up to six times daily, with each episode
lasting between 30 and 120 minutes.
More information about Cynapsus (TSX-V: CTH) (OTCQX: CYNAF) is
available at www.cynapsus.ca and at the System for Electronic
Document Analysis and Retrieval (SEDAR) at www.sedar.com.
Forward Looking Statements
This announcement contains "forward-looking statements" within
the meaning of applicable securities laws. Generally, these
forward-looking statements can be identified by the use of
forward-looking terminology such as "plans", "expects" or "does not
expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or
"believes" or variations of such words and phrases or state that
certain actions, events or results "may", "could", "would", "might"
or "will be taken", "occur" or "be achieved". Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that may cause the actual results, level of
activity, performance or achievements of Cynapsus to be materially
different from those expressed or implied by such forward-looking
statements, including but not limited to those risks and
uncertainties relating to Cynapsus’ business disclosed under the
heading “Risk Factors” in its March 26, 2014, Annual Information
Form and its other filings with the various Canadian securities
regulators which are available online at www.sedar.com. Although
Cynapsus has attempted to identify important factors that could
cause actual results to differ materially from those contained in
forward-looking statements, there may be other factors that cause
results not to be as anticipated, estimated or intended. There can
be no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements. Cynapsus does
not undertake to update any forward-looking statements, except in
accordance with applicable securities laws.
Neither the TSX Venture Exchange nor the OTCQX International has
approved or disapproved of the contents of this press release.
Cynapsus TherapeuticsAnthony Giovinazzo, 416-703-2449
x225President and CEOajg@cynapsus.caorAndrew Williams, 416-703-2449
x253COO & CFOawilliams@cynapsus.ca
Cotec (TSXV:CTH)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Cotec (TSXV:CTH)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
